

## APPENDIX

| Citation                                                                                                                                                                                                                                                                                                                                                                              | Total Citations | Citations per Year |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|--------------------|
| 1 Abrams, P., Schulman, C. C., Vaage, S., Abel, P., Baxby, K., Boeminghaus, F., . . . Ypma, A. (1995). TAMSULOSIN, A SELECTIVE ALPHA(1C)-ADRENOCEPTOR ANTAGONIST - A RANDOMIZED, CONTROLLED TRIAL IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION (SYMPTOMATIC BPH). <i>British Journal of Urology</i> , 76(3), 325-336. doi:10.1111/j.1464-410X.1995.tb07709.x                         | 184             | 8.00               |
| 2 Al-Ansari, A., Younes, N., Sampige, V. P., Al-Rumaihi, K., Ghafouri, A., Gul, T., & Shokeir, A. A. (2010). Green Light HPS 120-W Laser Vaporization Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Hyperplasia: A Randomized Clinical Trial with Midterm Follow-up. <i>European Urology</i> , 58(3), 349-355. doi:10.1016/j.eururo.2010.05.026    | 154             | 19.25              |
| 3 Barrow, J. C., Nantermet, P. G., Selnick, H. G., Glass, K. L., Rittle, K. E., Gilbert, K. F., . . . Forray, C. (2000). In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. <i>Journal of Medicinal Chemistry</i> , 43(14), 2703-2718. doi:10.1021/jm990612y | 185             | 10.28              |
| 4 Barry, M. J. (1990). EPIDEMIOLOGY AND NATURAL-HISTORY OF BENIGN PROSTATIC HYPERPLASIA. <i>Urologic Clinics of North America</i> , 17(3), 495-507.                                                                                                                                                                                                                                   | 173             | 6.18               |
| 5 Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., & Mebust, W. K. (1995). MEASURING DISEASE-SPECIFIC HEALTH-STATUS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. <i>Medical Care</i> , 33(4), AS145-AS155.                                                                                                                                               | 143             | 6.22               |
| 6 Barry, M. J., Fowler, F. J., Oleary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., . . . Wein, A. J. (1992). THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 148(5), 1549-1557. doi:10.1016/s0022-5347(17)36966-5                                                                                      | 2042            | 78.54              |
| 7 Bartsch, G., Muller, H. R., Oberholzer, M., & Rohr, H. P. (1979). LIGHT MICROSCOPIC STEREOLOGICAL ANALYSIS OF THE NORMAL HUMAN-PROSTATE AND OF BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 122(4), 487-491. doi:10.1016/s0022-5347(17)56476-9                                                                                                                         | 229             | 5.87               |
| 8 Bent, S., Kane, C., Shinohara, K., Neuhaus, J., Hudes, E. S., Goldberg, H., & Avins, A. L. (2006). Saw palmetto for benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 354(6), 557-566. doi:10.1056/NEJMoa053085                                                                                                                                                | 205             | 17.08              |
| 9 Berges, R. R., Windeler, J., Trampisch, H. J., Senge, T., Aeikens, B., Albrecht, J., . . . Schumacher, C. (1995). RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL-TRIAL OF BETA-SITOSTEROL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. <i>Lancet</i> , 345(8964), 1529-1532. doi:10.1016/s0140-6736(95)91085-9                                                             | 155             | 6.74               |
| 10 Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984). THE DEVELOPMENT OF HUMAN BENIGN PROSTATIC HYPERPLASIA WITH AGE. <i>Journal of Urology</i> , 132(3), 474-479. doi:10.1016/s0022-5347(17)49698-4                                                                                                                                                                   | 1366            | 40.18              |
| 11 Boyle, P., Gould, A. L., & Roehrborn, C. G. (1996). Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis                                                                                                                                                                                                                  | 313             | 14.23              |

- of randomized clinical trials. *Urology*, 48(3), 398-405. doi:10.1016/s0090-4295(96)00353-6
- 12 Carson, C., & Rittmaster, R. (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. *Urology*, 61(4), 2-7. doi:10.1016/s0090-4295(03)00045-1 165 11.00
  - 13 Chapple, C. R., Wyndaele, J. J., Nordling, J., Boeminghaus, F., Ypma, A., & Abrams, P. (1996). Tamsulosin, the first prostate-selective alpha(1A)-adrenoceptor antagonist - A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). *European Urology*, 29(2), 155-167 207 9.41
  - 14 Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004). Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. *Journal of Clinical Endocrinology & Metabolism*, 89(5), 2179-2184. doi:10.1210/jc.2003-030330 232 16.57
  - 15 Coffey, D. S., & Walsh, P. C. (1990). CLINICAL AND EXPERIMENTAL STUDIES OF BENIGN PROSTATIC HYPERPLASIA. *Urologic Clinics of North America*, 17(3), 461-475. 157 5.61
  - 16 Cordon-Cardo, C., Koff, A., Drobnjak, M., Capodieci, P., Osman, I., Millard, S. S., . . . Scher, H. I. (1998). Distinct altered patterns of p27(KIP1) gene expression in benign prostatic hyperplasia and prostatic carcinoma. *Journal of the National Cancer Institute*, 90(17), 1284-1291. doi:10.1093/jnci/90.17.1284 222 11.10
  - 17 Dahle, S. E., Chokkalingam, A. P., Gao, Y. T., Deng, J., Stanczyk, F. Z., & Hsing, A. W. (2002). Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. *Journal of Urology*, 168(2), 599-604. doi:10.1016/s0022-5347(05)64687-3 146 9.13
  - 18 De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schroder, F., . . . Tubaro, A. (2011). The Controversial Relationship Between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. *European Urology*, 60(1), 106-117. doi:10.1016/j.eururo.2011.03.055 159 22.71
  - 19 Debruyne, F., Barkin, J., van Erps, P., Reis, M., Tammela, T. L. J., Roehrborn, C., . . . Investigators, A. S. (2004). Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. *European Urology*, 46(4), 488-495. doi:10.1016/j.eururo.2004.05.008 149 10.64
  - 20 Debruyne, F. M. J., Jardin, A., Colloi, D., Resel, L., Witjes, W. P. J., Delauche-Cavallier, M. C., . . . European, A. S. G. (1998). Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. *European Urology*, 34(3), 169-175. doi:10.1159/000019706 163 8.15
  - 21 Di Silverio, F., Gentile, V., De Matteis, A., Mariotti, G., Giuseppe, V., Luigi, P. A., & Sciarra, A. (2003). Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: A retrospective analysis. *European Urology*, 43(2), 164-175. doi:10.1016/s0302-2838(02)00548-1 140 9.33
  - 22 Fawzy, A., Braun, K., Lewis, G. P., Gaffney, M., Ice, K., & Dias, N. (1995). DOXAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN NORMOTENSIVE PATIENTS - A MULTICENTER STUDY. *Journal of Urology*, 154(1), 105-109. doi:10.1016/s0022-5347(01)67240-9 154 6.70

|    |                                                                                                                                                                                                                                                                                                                                                                                        |     |       |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
| 23 | Fleming, W. H., Hamel, A., Macdonald, R., Ramsey, E., Pettigrew, N. M., Johnston, B., . . . Matusik, R. J. (1986). EXPRESSION OF THE CIS-MYC PROTOONCOGENE IN HUMAN PROSTATIC-CARCINOMA AND BENIGN PROSTATIC HYPERPLASIA. <i>Cancer Research</i> , 46(3), 1535-1538                                                                                                                    | 155 | 4.84  |
| 24 | Fulton, B., Wagstaff, A. J., & Sorkin, E. M. (1995). DOXAZOSIN - AN UPDATE OF ITS CLINICAL-PHARMACOLOGY AND THERAPEUTIC APPLICATIONS IN HYPERTENSION AND BENIGN PROSTATIC HYPERPLASIA. <i>Drugs</i> , 49(2), 295-320. doi:10.2165/00003495-199549020-00011                                                                                                                             | 144 | 6.26  |
| 25 | Gacci, M., Corona, G., Salvi, M., Vignozzi, L., McVary, K. T., Kaplan, S. A., . . . Maggi, M. (2012). A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with alpha-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. <i>European Urology</i> , 61(5), 994-1003. doi:10.1016/j.eururo.2012.02.033 | 145 | 24.17 |
| 26 | Garraway, W. M., Russell, E., Lee, R. J., Collins, G. N., McKelvie, G. B., Hehir, M., . . . Simpson, R. J. (1993). IMPACT OF PREVIOUSLY UNRECOGNIZED BENIGN PROSTATIC HYPERPLASIA ON THE DAILY ACTIVITIES OF MIDDLE-AGED AND ELDERLY MEN. <i>British Journal of General Practice</i> , 43(373), 318-321.                                                                               | 141 | 5.64  |
| 27 | Gillenwater, J. Y., Conn, R. L., Chrysant, S. G., Roy, J., Gaffney, M., Ice, K., & Dias, N. (1995). DOXAZOSIN FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION - A DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RESPONSE MULTICENTER STUDY. <i>Journal of Urology</i> , 154(1), 110-115. doi:10.1016/s0022-5347(01)67243-4          | 153 | 6.65  |
| 28 | Giovannucci, E., Rimm, E. B., Chute, C. G., Kawachi, I., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994). OBESITY AND BENIGN PROSTATIC HYPERPLASIA. <i>American Journal of Epidemiology</i> , 140(11), 989-1002. doi:10.1093/oxfordjournals.aje.a117206                                                                                                                       | 162 | 6.75  |
| 29 | Glynn, R. J., Campion, E. W., Bouchard, G. R., & Silbert, J. E. (1985). THE DEVELOPMENT OF BENIGN PROSTATIC HYPERPLASIA AMONG VOLUNTEERS IN THE NORMATIVE AGING STUDY. <i>American Journal of Epidemiology</i> , 121(1), 78-90.                                                                                                                                                        | 272 | 8.24  |
| 30 | Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperatomcginley, J., Walsh, P. C., McConnell, J. D., . . . Ng, J. (1992). THE EFFECT OF FINASTERIDE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. <i>New England Journal of Medicine</i> , 327(17), 1185-1191. doi:10.1056/nejm199210223271701                                                                                             | 836 | 32.15 |
| 31 | Griffiths, D., Vanmastrigt, R., & Bosch, R. (1989). QUANTITIFICATION OF URETHRAL RESISTANCE AND BLADDER FUNCTION DURING VOIDING, WITH SPECIAL REFERENCE TO THE EFFECTS OF PROSTATE SIZE-REDUCTION ON URETHRAL OBSTRUCTION DUE TO BENIGN PROSTATIC HYPERPLASIA. <i>Neurourology and Urodynamics</i> , 8(1), 17-27. doi:10.1002/nau.1930080104                                           | 148 | 5.10  |
| 32 | Hammarsten, J., & Hogstedt, B. (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. <i>European Urology</i> , 39(2), 151-158. doi:10.1159/000052430                                                                                                                                                                                                 | 190 | 11.18 |

|    |                                                                                                                                                                                                                                                                                                                                                                                                         |     |       |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
| 33 | Hammarsten, J., Hogstedt, B., Holthuis, N., & Mellstrom, D. (1998). Components of the metabolic syndrome - risk factors for the development of benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 1(3), 157-162. doi:10.1038/sj.pcan.4500221                                                                                                                                 | 178 | 8.90  |
| 34 | Kawabe, K., Yoshida, M., Homma, Y., & Silodosin Clin Study, G. (2006). Silodosin, a new alpha(1A)-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. <i>Bju International</i> , 98(5), 1019-1024. doi:10.1111/j.1464-410X.2006.06448.x                                             | 165 | 13.75 |
| 35 | Kenny, B., Ballard, S., Blagg, J., & Fox, D. (1997). Pharmacological options in the treatment of benign prostatic hyperplasia. <i>Journal of Medicinal Chemistry</i> , 40(9), 1293-1315. doi:10.1021/jm960697s                                                                                                                                                                                          | 154 | 7.33  |
| 36 | Kirby, R. S., Roehrborn, C., Boyle, P., Bartsch, G., Jardin, A., Cary, M. M., . . . Predict Study, I. (2003). Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The Prospective European Doxazosin and Combination Therapy (PREDICT) trial. <i>Urology</i> , 61(1), 119-126. doi:10.1016/s0090-4295(02)02114-3 | 221 | 14.73 |
| 37 | Kramer, G., Mitteregger, D., & Marberger, M. (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? <i>European Urology</i> , 51(5), 1202-1216. doi:10.1016/j.eururo.2006.12.011                                                                                                                                                                                                 | 236 | 21.45 |
| 38 | Krieg, M., Klotzl, G., Kaufmann, J., & Voigt, K. D. (1981). STROMA OF HUMAN BENIGN PROSTATIC HYPERPLASIA - PREFERENTIAL TISSUE FOR ANDROGEN METABOLISM AND ESTROGEN BINDING. <i>Acta Endocrinologica</i> , 96(3), 422-432.                                                                                                                                                                              | 144 | 3.89  |
| 39 | Kurhanewicz, J., Vigneron, D. B., Nelson, S. J., Hricak, H., Macdonald, J. M., Konety, B., & Narayan, P. (1995). CITRATE AS AN IN-VIVO MARKER TO DISCRIMINATE PROSTATE-CANCER FROM BENIGN PROSTATIC HYPERPLASIA AND NORMAL PROSTATE PERIPHERAL ZONE - DETECTION VIA LOCALIZED PROTON SPECTROSCOPY. <i>Urology</i> , 45(3), 459-466. doi:10.1016/s0090-4295(99)80016-8                                   | 147 | 6.39  |
| 40 | Lepor, H. (1995). LONG-TERM EFFICACY AND SAFETY OF TERAZOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA. <i>Urology</i> , 45(3), 406-413. doi:10.1016/s0090-4295(99)80008-9                                                                                                                                                                                                                          | 271 | 13.55 |
| 41 | Lepor, H., & Tamsulosin Investigator, G. (1998). Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of Phase III trial. <i>Urology</i> , 51(6), 901-906. doi:10.1016/s0090-4295(98)00127-7                                                                                                                                                  | 151 | 7.55  |
| 42 | Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., . . . Padley, R. J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 335(8), 533-539. doi:10.1056/nejm199608223350801                                                                                                             | 149 | 6.48  |
| 43 | Lepor, H., Auerbach, S., Purasbaez, A., Narayan, P., Soloway, M., Lowe, F., . . . Madsen, P. (1992). A RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF TERAZOSIN IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 148(5), 1467-1474. doi:10.1016/s0022-5347(17)36941-0                                                                      | 272 | 10.46 |

|    |                                                                                                                                                                                                                                                                                                                                                                                                    |      |       |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-------|
| 44 | Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., . . . Padley, R. J. (1996). The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 335(8), 533-539. doi:10.1056/nejm199608223350801                                                                                                        | 552  | 25.09 |
| 45 | Luo, J., Duggan, D. J., Chen, Y. D., Sauvageot, J., Ewing, C. M., Bittner, M. L., . . . Isaacs, W. B. (2001). Human prostate cancer and benign prostatic hyperplasia: Molecular dissection by gene expression profiling. <i>Cancer Research</i> , 61(12), 4683-4688.                                                                                                                               | 374  | 22.00 |
| 46 | Madersbacher, S., Alivizatos, G., Nordling, J., Sanz, C. R., Emberton, M., & de la Rosette, J. (2004). EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). <i>European Urology</i> , 46(5), 547-554. doi:10.1016/j.eururo.2004.07.016                                                   | 404  | 28.86 |
| 47 | Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., & Adami, H. O. (1997). Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. <i>British Journal of Cancer</i> , 76(9), 1115-1118. doi:10.1038/bjc.1997.520                                                                                                                | 284  | 13.52 |
| 48 | Maria, G., Brisinda, G., Civello, I. M., Bentivoglio, A. R., Sganga, G., & Albanese, A. (2003). Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. <i>Urology</i> , 62(2), 259-264. doi:10.1016/s0090-4295(03)00477-1                                                                                        | 167  | 11.13 |
| 49 | McConnell, J. D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H. L., . . . Finasteride Long-Term Eff Saf Study, G. (1998). The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 338(9), 557-563. doi:10.1056/nejm199802263380901         | 732  | 36.60 |
| 50 | McConnell, J. D., Roehrborn, C. G., Bautista, O. M., Andriole, G. L., Dixon, C. M., Kusek, J. W., . . . Grp, M. R. (2003). The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. <i>New England Journal of Medicine</i> , 349(25), 2387-2398. doi:10.1056/NEJMoa030656                                              | 1036 | 69.07 |
| 51 | McConnell, J. D., Wilson, J. D., George, F. W., Geller, J., Pappas, F., & Stoner, E. (1992). FINASTERIDE, AN INHIBITOR OF 5-ALPHA-REDUCTASE, SUPPRESSES PROSTATIC DIHYDROTESTOSTERONE IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> , 74(3), 505-508. doi:10.1210/jc.74.3.505                                                                | 266  | 10.23 |
| 52 | McNeal, J. (1990). PATHOLOGY OF BENIGN PROSTATIC HYPERPLASIA - INSIGHT INTO ETIOLOGY. <i>Urologic Clinics of North America</i> , 17(3), 477-486.                                                                                                                                                                                                                                                   | 209  | 7.46  |
| 53 | McVary, K. T., Monnig, W., Camps, J. L., Young, J. M., Tseng, L. J., & van den Ende, G. (2007). Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. <i>Journal of Urology</i> , 177(3), 1071-1077. doi:10.1016/j.juro.2006.10.055 | 234  | 21.27 |
| 54 | McVary, K. T., Roehrborn, C. G., Avins, A. L., Barry, M. J., Bruskewitz, R. C., Donnell, R. F., . . . Wei, J. T. (2011). Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 185(5), 1793-1803. doi:10.1016/j.juro.2011.01.074                                                                                                                  | 437  | 62.43 |

|    |                                                                                                                                                                                                                                                                                                                                                                                         |     |       |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
| 55 | McVary, K. T., Roehrborn, C. G., Kaminetsky, J. C., Auerbach, S. M., Wachs, B., Young, J. M., . . . Denes, B. S. (2007). Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Journal of Urology</i> , 177(4), 1401-1407. doi:10.1016/j.juro.2006.11.037                                                                                       | 234 | 21.27 |
| 56 | McVary, K. T. (2006). BPH: Epidemiology and comorbidities. <i>American Journal of Managed Care</i> , 12(5), S122-S128.                                                                                                                                                                                                                                                                  | 168 | 14.00 |
| 57 | McVary, K. T. (2005). Erectile dysfunction and lower urinary tract symptoms secondary to BPH. <i>European Urology</i> , 47(6), 838-845. doi:10.1016/j.eururo.2005.02.001                                                                                                                                                                                                                | 140 | 10.77 |
| 58 | McVary, K. T., Rademaker, A., Lloyd, G. L., & Gann, P. (2005). Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>Journal of Urology</i> , 174(4), 1327-1333. doi:10.1097/01.ju.0000173072.73702.64                                                                                                           | 145 | 11.15 |
| 59 | Meigs, J. B., Mohr, B., Barry, M. J., Collins, M. M., & McKinlay, J. B. (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. <i>Journal of Clinical Epidemiology</i> , 54(9), 935-944. doi:10.1016/s0895-4356(01)00351-1                                                                                                | 222 | 13.06 |
| 60 | Montorsi, F., Naspro, R., Salonia, A., Suardi, N., Briganti, A., Zanoni, M., . . . Rigatti, P. (2004). Holmium laser enucleation versus transurethral resection of the prostate: Results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. <i>Journal of Urology</i> , 172(5), 1926-1929. doi:10.1097/01.ju.0000140501.68841.a1 | 158 | 11.29 |
| 61 | Mori, H., Maki, M., Oishi, K., Jaye, M., Igarashi, K., Yoshida, O., & Hatanaka, M. (1990). INCREASED EXPRESSION OF GENES FOR BASIC FIBROBLAST GROWTH-FACTOR AND TRANSFORMING GROWTH-FACTOR TYPE-BETA-2 IN HUMAN BENIGN PROSTATIC HYPERPLASIA. <i>Prostate</i> , 16(1), 71-80. doi:10.1002/pros.2990160108                                                                               | 169 | 6.04  |
| 62 | Nadler, R. B., Humphrey, P. A., Smith, D. S., Catalona, W. J., & Ratliff, T. L. (1995). EFFECT OF INFLAMMATION AND BENIGN PROSTATIC HYPERPLASIA ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN LEVELS. <i>Journal of Urology</i> , 154(2), 407-413. doi:10.1016/s0022-5347(01)67064-2                                                                                                      | 275 | 11.96 |
| 63 | Narayan, P., Tewari, A., & Grp, U. S. S. (1998). A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. <i>Journal of Urology</i> , 160(5), 1701-1706. doi:10.1016/s0022-5347(01)62386-3                                                                                        | 141 | 7.05  |
| 64 | Nickel, J. C., Downey, J., Young, I., & Boag, S. (1999). Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. <i>Bju International</i> , 84(9), 976-981.                                                                                                                                                                                                         | 206 | 10.84 |
| 65 | Nickel, J. C., Fradet, Y., Boake, R. C., Pommerville, P. J., Perreault, J. P., Afridi, S. K., . . . Williams, J. A. (1996). Efficacy and safety off finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT Study). <i>Canadian Medical Association Journal</i> , 155(9), 1251-1259.                                        | 161 | 7.32  |
| 66 | Oelke, M., Giuliano, F., Mirone, V., Xu, L., Cox, D., & Viktrup, L. (2012). Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial. <i>European Urology</i> , 61(5), 917-925. doi:10.1016/j.eururo.2012.01.013                | 150 | 25.00 |

|    |                                                                                                                                                                                                                                                                                                                                                                                             |     |       |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
| 67 | Oesterling, J. E. (1995). DRUG-THERAPY - BENIGN PROSTATIC HYPERPLASIA - MEDICAL AND MINIMALLY INVASIVE TREATMENT OPTIONS. <i>New England Journal of Medicine</i> , 332(2), 99-109. doi:10.1056/nejm199501123320207                                                                                                                                                                          | 174 | 7.57  |
| 68 | Oto, A., Kayhan, A., Jiang, Y. L., Tretiakova, M., Yang, C., Antic, T., . . . Stadler, W. M. (2010). Prostate Cancer: Differentiation of Central Gland Cancer from Benign Prostatic Hyperplasia by Using Diffusion-weighted and Dynamic Contrast-enhanced MR Imaging. <i>Radiology</i> , 257(3), 715-723. doi:10.1148/radiol.10100021                                                       | 153 | 19.13 |
| 69 | Ozden, C., Ozdal, O. L., Uryancioglu, G., Koyuncu, H., Gokkaya, S., & Memis, A. (2007). The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. <i>European Urology</i> , 51(1), 199-206. doi:10.1016/j.eururo.2006.05.040                                                                                                           | 145 | 13.18 |
| 70 | Parsons, J. K., Carter, H. B., Partin, A. W., Windham, B. G., Metter, E. J., Ferrucci, L., . . . Platz, E. A. (2006). Metabolic factors associated with benign prostatic hyperplasia. <i>Journal of Clinical Endocrinology &amp; Metabolism</i> , 91(7), 2562-2568. doi:10.1210/jc.2005-2799                                                                                                | 190 | 15.83 |
| 71 | Partin, A. W., Getzenberg, R. H., Carmichael, M. J., Vindivich, D., Yoo, J., Epstein, J. I., & Coffey, D. S. (1993). NUCLEAR MATRIX PROTEIN-PATTERNS IN HUMAN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE-CANCER. <i>Cancer Research</i> , 53(4), 744-746.                                                                                                                                    | 142 | 5.68  |
| 72 | Partin, A. W., Oesterling, J. E., Epstein, J. I., Horton, R., & Walsh, P. C. (1991). INFLUENCE OF AGE AND ENDOCRINE FACTORS ON THE VOLUME OF BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 145(2), 405-409. doi:10.1016/s0022-5347(17)38353-2                                                                                                                                   | 140 | 5.19  |
| 73 | Penna, G., Mondaini, N., Amuchastegui, S., Innocenti, S. D., Carini, M., Giubilei, G., . . . Adorini, L. (2007). Seminal plasma cytokines and chemokines in prostate inflammation: Interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. <i>European Urology</i> , 51(2), 524-533. doi:10.1016/j.eururo.2006.07.016 | 141 | 12.82 |
| 74 | Peters, C. A., & Walsh, P. C. (1987). THE EFFECT OF NAFARELIN ACETATE, A LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST, ON BENIGN PROSTATIC HYPERPLASIA. <i>New England Journal of Medicine</i> , 317(10), 599-604. doi:10.1056/nejm198709033171004                                                                                                                                         | 279 | 9.00  |
| 75 | Peters, T. J., Donovan, J. L., Kay, H. E., Abrams, P., delaRosette, J., Porru, D., . . . Walter. (1997). The international continence society "benign prostatic hyperplasia" study: The bothersomeness of urinary symptoms. <i>Journal of Urology</i> , 157(3), 885-889. doi:10.1016/s0022-5347(01)65075-4                                                                                  | 239 | 11.38 |
| 76 | Reich, O., Gratzke, C., & Stief, C. G. (2006). Techniques and long-term results of surgical procedures for BPH. <i>European Urology</i> , 49(6), 970-978. doi:10.1016/j.eururo.2005.12.072                                                                                                                                                                                                  | 164 | 13.67 |
| 77 | Roehrborn, C. G., Boyle, P., Gould, A. L., & Waldstreicher, J. (1999). Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. <i>Urology</i> , 53(3), 581-589. doi:10.1016/s0090-4295(98)00655-4                                                                                                                                       | 206 | 10.84 |
| 78 | Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., Investigators, A. S., . . . Investigators, A. S. (2002). Efficacy and safety of a dual inhibitor of 5-alpha-                                                                                                                                                                                                         | 431 | 26.94 |

|    |                                                                                                                                                                                                                                                                                                                                                                                                          |     |       |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
|    | reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. <i>Urology</i> , 60(3), 434-441. doi:10.1016/s0090-4295(02)01905-2                                                                                                                                                                                                                                                       |     |       |
| 79 | Roehrborn, C. G., McConnell, J. D., Lieber, M., Kaplan, S., Geller, J., Malek, G. H., . . . Grp, P. S. (1999). Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. <i>Urology</i> , 53(3), 473-480. doi:10.1016/s0090-4295(98)00654-2                                               | 209 | 11.00 |
| 80 | Roehrborn, C. G., Oesterling, J. E., Auerbach, S., Kaplan, S. A., Lloyd, L. K., Milam, D. E., & Padley, R. J. (1996). The Hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. <i>Urology</i> , 47(2), 159-168. doi:10.1016/s0090-4295(99)80409-9                                                | 167 | 7.59  |
| 81 | Roehrborn, C. G., & Schwinn, D. A. (2004). alpha(1)-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. <i>Journal of Urology</i> , 171(3), 1029-1035. doi:10.1097/01.ju.0000097026.43866.cc                                                                                                                                                     | 186 | 13.29 |
| 82 | Roehrborn, C. G., McVary, K. T., Elion-Mboussa, A., & Viktrup, L. (2008). Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: A dose finding study. <i>Journal of Urology</i> , 180(4), 1228-1234. doi:10.1016/j.juro.2008.06.079                                                                                                              | 176 | 17.60 |
| 83 | Roehrborn, C. G., Siami, P., Barkin, J., Damiao, R., Major-Walker, K., Morrill, B., . . . Comb, A. T. S. G. (2008). The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. <i>Journal of Urology</i> , 179(2), 616-621. doi:10.1016/j.juro.2007.09.084 | 176 | 17.60 |
| 84 | Roehrborn, C. G., Siami, P., Barkin, J., Damiao, R., Major-Walker, K., Nandy, I., . . . Comb, A. T. S. G. (2010). The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. <i>European Urology</i> , 57(1), 123-131. doi:10.1016/j.eururo.2009.09.035                         | 323 | 40.38 |
| 85 | Roos, N. P., Wennberg, J. E., Malenka, D. J., Fisher, E. S., McPherson, K., Andersen, T. F., . . . Ramsey, E. (1989). MORTALITY AND REOPERATION AFTER OPEN AND TRANS-URETHRAL RESECTION OF THE PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA. <i>New England Journal of Medicine</i> , 320(17), 1120-1124. doi:10.1056/nejm198904273201705                                                                   | 494 | 17.03 |
| 86 | Shapiro, E., Hartanto, V., & Lepor, H. (1992). THE RESPONSE TO ALPHA-BLOCKADE IN BENIGN PROSTATIC HYPERPLASIA IS RELATED TO THE PERCENT AREA DENSITY OF PROSTATE SMOOTH-MUSCLE. <i>Prostate</i> , 21(4), 297-307. doi:10.1002/pros.2990210406                                                                                                                                                            | 140 | 5.38  |
| 87 | Stamey, T. A., Warrington, J. A., Caldwell, M. C., Chen, Z. X., Fan, Z. B., Mahadevappa, M., . . . Zhang, Z. M. (2001). Molecular genetic profiling of gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. <i>Journal of Urology</i> , 166(6), 2171-2177. doi:10.1016/s0022-5347(05)65528-0                                                                                     | 144 | 8.47  |
| 88 | Stief, C. G., Porst, H., Neuser, D., Beneke, M., & Ulbrich, E. (2008). A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. <i>European Urology</i> , 53(6), 1236-1244. doi:10.1016/j.eururo.2008.01.075                                                                  | 189 | 18.90 |

|     |                                                                                                                                                                                                                                                                                                                                                                                                                                                    |     |       |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-------|
| 89  | Stoner, E. (1992). THE CLINICAL EFFECTS OF A 5-ALPHA-REDUCTASE INHIBITOR, FINASTERIDE, ON BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 147(5), 1298-1302. doi:10.1016/s0022-5347(17)37547-x                                                                                                                                                                                                                                           | 149 | 5.73  |
| 90  | Stoner, E., Andriole, G. L., Boake, R., Bracken, B. R., Brannan, W., Fuselier, H., . . . Charig, C. (1994). 3-YEAR SAFETY AND EFFICACY DATA ON THE USE OF FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA. <i>Urology</i> , 43(3), 284-294. doi:10.1016/0090-4295(94)90068-x                                                                                                                                                          | 167 | 6.96  |
| 91  | Tan, A. H. H., Gilling, P. J., Kennett, K. M., Frampton, C., Westenberg, A. M., & Fraundorfer, M. R. (2003). A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign prostatic hyperplasia in large glands (40 to 200 grams). <i>Journal of Urology</i> , 170(4), 1270-1274. doi:10.1097/01.ju.0000086948.55973.00 | 187 | 12.47 |
| 92  | Te, A. E., Malloy, T. R., Stein, B. S., Ulchaker, J. C., Nseyo, U. O., Hai, M. A., & Malek, R. S. (2004). Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. <i>Journal of Urology</i> , 172(4), 1404-1408. doi:10.1097/01.ju.0000139541.68542.f6                                                                         | 167 | 11.93 |
| 93  | Theyer, G., Kramer, G., Assmann, I., Sherwood, E., Preinfalk, W., Marberger, M., . . . Steiner, G. E. (1992). PHENOTYPIC CHARACTERIZATION OF INFILTRATING LEUKOCYTES IN BENIGN PROSTATIC HYPERPLASIA. <i>Laboratory Investigation</i> , 66(1), 96-107.                                                                                                                                                                                             | 152 | 5.85  |
| 94  | Thorpe, A., & Neal, D. (2003). Benign prostatic hyperplasia. <i>Lancet</i> , 361(9366), 1359-1367. doi:10.1016/s0140-6736(03)13073-5                                                                                                                                                                                                                                                                                                               | 147 | 9.80  |
| 95  | Untergasser, G., Madersbacher, S., & Berger, P. (2005). Benign prostatic hyperplasia: age-related tissue-remodeling. <i>Experimental Gerontology</i> , 40(3), 121-128. doi:10.1016/j.exger.2004.12.008                                                                                                                                                                                                                                             | 144 | 11.08 |
| 96  | Verhamme, K. M. C., Dieleman, J. P., Bleumink, G. S., van der Lei, J., & Sturkenboom, M. (2002). Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - The Triumph project. <i>European Urology</i> , 42(4), 323-328. doi:10.1016/s0302-2838(02)00354-8                                                                                                                            | 177 | 11.06 |
| 97  | Wasson, J. H., Reda, D. J., Bruskewitz, R. C., Elinson, J., Keller, A. M., & Henderson, W. G. (1995). A COMPARISON OF TRANSURETHRAL SURGERY WITH WATCHFUL WAITING FOR MODERATE SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. <i>New England Journal of Medicine</i> , 332(2), 75-79. doi:10.1056/nejm199501123320202                                                                                                                                   | 403 | 17.52 |
| 98  | Wei, J. T., Calhoun, E., & Jacobsen, S. J. (2005). Urologic diseases in America project: Benign prostatic hyperplasia. <i>Journal of Urology</i> , 173(4), 1256-1261. doi:10.1097/01.ju.0000155709.37840.fe                                                                                                                                                                                                                                        | 276 | 21.23 |
| 99  | Wilson, J. D. (1980). THE PATHOGENESIS OF BENIGN PROSTATIC HYPERPLASIA. <i>American Journal of Medicine</i> , 68(5), 745-756. doi:10.1016/0002-9343(80)90267-3                                                                                                                                                                                                                                                                                     | 322 | 8.47  |
| 100 | Wilt, T. J., Ishani, A., Stark, G., MacDonald, R., Lau, J., & Mulrow, C. (1998). Saw palmetto extracts for treatment of benign prostatic hyperplasia - A systematic review. <i>Jama-Journal of the American Medical Association</i> , 280(18), 1604-1609. doi:10.1001/jama.280.18.1604                                                                                                                                                             | 226 | 11.30 |